The Fist Affiliated Hospital of USTC(Anhui Provincial hospital)
Welcome,         Profile    Billing    Logout  
 0 Trials 
19 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Lianxin
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting
3
480
RoW
Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
08/24
12/26
SHR-8068-301, NCT06618664: Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Recruiting
3
560
RoW
SHR-8068, Adebrelimab, Bevacizumab, Sintilimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Hepatocellular Carcinoma
03/26
12/30
NCT04741165: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Recruiting
2
72
RoW
HX008, Bevacizumab, AVASTIN®, Lenvatinib, LENVIMA®
Taizhou Hanzhong biomedical co. LTD
Hepatocellular Carcinoma
04/22
10/22
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Recruiting
2
40
RoW
TQ05105 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Graft Versus Host Disease
10/25
04/26
NCT06498622: Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Recruiting
2
45
RoW
Donafenib + Envafolimab
Anhui Provincial Hospital
Hepatocellular Carcinoma
05/27
05/27
NCT06673498: Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

Recruiting
2
60
RoW
Lusutrombopag combined with recombinant human thrombopoietin
Anhui Provincial Hospital
Thrombocytopenia
11/25
11/25
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
2
70
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Intrahepatic Cholangiocarcinoma (ICC)
05/26
12/26
BGB-Sitra-2001-IIT, NCT05407519: A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Recruiting
2
40
RoW
Tislelizumab + Sitravatinib
Anhui Provincial Hospital, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital
Hepatocellular Carcinoma
06/26
06/26
NCT05444088: Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting
1/2
129
RoW
Adebrelimab, Bevacizumab, SHR-8068
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Hepatocellular Carcinoma
06/26
06/26
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Recruiting
1
40
RoW
NRT6003 Injection, Yttrium-90 carbon microspheres
Chengdu New Radiomedicine Technology Co. LTD.
Unresectable Hepatocellular Carcinoma
10/25
10/25
NCT06296095: To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis

Enrolling by invitation
1
9
RoW
Cell therapy
Anhui Provincial Hospital
Cirrhosis, Liver
10/24
12/24
TQB3006-I-01, NCT06344351: A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer

Recruiting
1
112
RoW
TQB3006 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Malignant Neoplasm
03/25
08/26
NCT06671275: A Clinical Study to Evaluate CUD005 Injection in Patients with Liver Cirrhosis

Enrolling by invitation
1
9
RoW
Cell therapy
Anhui Provincial Hospital
Cirrhosis Liver
10/25
07/26
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Active, not recruiting
1
54
Europe, US, RoW
KIN-3248
Kinnate Biopharma
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
06/26
09/26
CRGGC, NCT04140552: Chinese Research Group of Gallbladder Cancer

Recruiting
N/A
10000
RoW
Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital
Gallbladder Neoplasms
12/22
12/25
NCT05457374: A Clinical Study of Portal Vein Embolization and Liver Venous Deprivation

Recruiting
N/A
10
RoW
PVE, LVD
Anhui Provincial Hospital
Liver Venous Deprivation
03/24
03/25
NCT06611345: A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

Recruiting
N/A
60
RoW
Tumor Treating Fields, Durvalumab, Gemcitabine, Cisplatin
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, AstraZeneca
Biliary Tract Cancers (BTC)
10/26
03/27
NCT06777485: China Liver Cancer Clinical Registry Cohort Database

Recruiting
N/A
10000
RoW
Procedure/Surgery treatment, Anti-Tumor Drugs
Anhui Provincial Hospital
Liver Cancer
01/35
01/35
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer with PVTT, HVTT or IVCTT After Initial Ate/Bev

Active, not recruiting
N/A
501
RoW
Atezolizumab, Bevacizumab, Surgery
Jia Fan
Venous Thrombosis
08/27
03/28

Download Options